Home > Insider Trading > Filing (0001209191-19-043886)

Filing Details

Accession Number:: 0001209191-19-043886
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-07-31 17:38:13
Reporting Period:: 2019-07-29

Accepted Time:: 2019-07-31 17:38:13
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1447362	Castle Biosciences Inc	CSTL	Services-Medical Laboratories (8071)	770701744

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1783205	Iii C. Joseph Cook	C/O Castle Biosciences, Inc. 820 S. Friendswood Drive, Suite 201 Friendswood TX 77546		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-07-29	1,336,927	$0.00	1,336,927	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2019-07-29	97,428	$12.80	1,434,355	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2019-07-29	312,500	$16.00	1,746,855	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2019-07-29	169,086	$0.00	169,086	No	4	C	Direct
Common Stock	Acquisiton	2019-07-29	16,722	$12.80	185,808	No	4	C	Direct
Common Stock	Acquisiton	2019-07-29	22,245	$16.00	208,053	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	P	Indirect	See footnotes
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2019-07-29	19,524	$0.00	16,015	$0.00
Common Stock	Series B Preferred Stock	Disposition	2019-07-29	122,158	$0.00	100,210	$0.00
Common Stock	Series D Preferred Stock	Disposition	2019-07-29	15,918	$0.00	13,058	$0.00
Common Stock	Series D Preferred Stock	Disposition	2019-07-29	337,754	$0.00	277,074	$0.00
Common Stock	Series E-1 Preferred Stock	Disposition	2019-07-29	463,453	$0.00	380,190	$0.00
Common Stock	Series E-2 Preferred Stock	Disposition	2019-07-29	5,461	$0.00	4,479	$0.00
Common Stock	Series E-2 Preferred Stock	Disposition	2019-07-29	158,379	$0.00	129,925	$0.00
Common Stock	Series E-3 Preferred Stock	Disposition	2019-07-29	4,681	$0.00	3,840	$0.00
Common Stock	Series E-3 Preferred Stock	Disposition	2019-07-29	142,843	$0.00	117,180	$0.00
Common Stock	Series F Preferred Stock	Disposition	2019-07-29	57,899	$0.00	47,495	$0.00
Common Stock	Series F Preferred Stock	Disposition	2019-07-29	507,762	$0.00	416,537	$0.00
Common Stock	Convertible Promissory Note	Disposition	2019-07-29	0	$0.00	16,722	$12.80
Common Stock	Convertible Promissory Note	Disposition	2019-07-29	0	$0.00	97,428	$12.80

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Direct
No	4	C	Direct
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Direct
No	4	C	Indirect
No	4	C	Direct
No	4	C	Indirect
No	4	C	Direct
No	4	C	Indirect
No	4	C	Direct
No	4	C	Indirect

Footnotes

The shares of Common Stock issued upon conversion of the Preferred Stock were calculated by first aggregating all series of Preferred Stockheld by the Reporting Person, in accordance with the terms of the Company's then-effective Certificate of Incorporation.
Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date.
Held by MGC Venture Partners 2013, L.P. ("MGC 2013 LP"). MGC Venture Partners 2013 GP, LLC ("MGC 2013 GP") is the general partner of MGC 2013 LP.
The Reporting Person is a managing director of MGC 2013 GP and a managing partner of MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP"), and shares voting and investment power over the shares held by MGC 2013 LP, MGC Venture Partners 2018, L.P. ("MGC 2018 LP") and MGC Venture Partners QP 2018, L.P. ("MGC QP 2018 LP"). The Reporting Person disclaims beneficial ownership of the shares held by MGC 2013 GP, MGC 2018 GP, MGC 2013 LP, MGC 2018 LP and MGC QP 2018 LP as reported herein, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owners of such securities for purposes of Section 16 or for any other purposes.
The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $1,200,000.00. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 80% of the IPO price per share of $16.00 per share.
Represents a purchase from the underwriters in the Issuer's IPO.
Held by MGC 2013 LP, MGC 2018 LP and MGC QP 2018 LP. MGC 2018 GP is the general partner of MGC 2018 LP and MGC QP 2018 LP.
The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $205,970.51. Upon closing of the IPO, the Conversion Amount automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 80% of the IPO price per share of $16.00 per share.